Effectiveness of surgical banding for high flow in brachial artery-based hemodialysis vascular access

Abstract

An immediate postbanding access flow >1 L/min and young age are risk factors for recurrent high flow in a banded brachial artery-based HD access during a 1-year follow-up.

The role of precision banding of arteriovenous fistulas in successful kidney transplant recipients

“…Success with flow reduction <1000 mL/min has been demonstrated in other studies and has been effective in other AV fistula problems, such as venous hypertension associated with central venous stenosis or occlusion. 5,6…”

Three Year Patency and Recurrence Rates of Revision Using Distal Inflow with a Venous Interposition Graft for High Flow Brachial Artery Based Arteriovenous Fistula

“…10 Unfortunately, half of the banded patients demonstrated recurrent high flow after 1 year. 12 The present 1 year results demonstrate a two third recurrence free survival indicating that RUDI does perform better at this time point, although direct comparisons are absent. However, one recurrence for every two RUDIs after 3 years is disappointing.…”

“…Banding, a previously recommended flow reducing technique, is beneficial in the short term but high flow often recurs. 12 Most patients undergoing revision using distal inflow (RUDI) were still free of high flow after 1 year, 15 but the efficacy of this technique is unknown beyond this time period. The aims of the present study were to investigate long-term rates of access patency and high flow recurrence after RUDI.…”

“…Immediate high post-operative flow and young age, factors also identified in a previous study, predicted recurrence. 12 It may be concluded that the optimal flow reducing technique resulting in durable stable access flows is yet to be discovered.…”

“…10 Although median-term results demonstrated recurrent high flow in up to half of the banded patients within 1 year. 11,12 An alternative method for flow reduction is termed revision using distal inflow (RUDI). This approach has been popularised for treating both HFA and HAIDI in brachial artery based AVFs.…”